Pro Medicus (ASX:PME), the Melbourne-based medical imaging software company, has added one of Australia's best-known technology executives to its board. In an ASX announcement on Wednesday, 23 September 2026, the company said Tim Reed, the former chief executive of accounting software group MYOB, would join as an independent non-executive director, effective 1 October 2026.

For an S&P/ASX 200 company whose growth is driven by selling cloud-based software into large US health systems, that combination of software Leadership and board experience is a logical and timely fit.

Who is Tim Reed?

Pro Medicus announcement, Mr Reed has more than 30 years of experience across technology, strategy, Business development and investment. He was chief executive of MYOB from 2008 to 2019, a period in which the company pursued growth and a shift to cloud-based products.

He is co-managing director of Potentia Capital, a technology-focused Private Equity firm, and currently sits on the board of toll road operator Transurban. He is also president of the GWS Giants AFL club and a member of the Climate Change Authority, and is a former president of the Business Council of Australia.

The announcement notes that he holds an MBA from Harvard Business School, where he was a Baker Scholar, and a Bachelor of Commerce with first class honours in Economics from the University of Melbourne.

The 's markets blog, reporting the appointment on Wednesday morning, highlighted his three decades of technology experience, his time at Potentia Capital and his Transurban directorship.

Why the appointment matters

Pro Medicus is one of the larger technology companies on the ASX by market value, and it still operates with a founder-led structure. Its board, listed on the company website, includes co-founders Dr Sam Hupert, the managing director and chief executive, and Anthony Hall, the technology director, alongside chair Peter Kempen and non-executive directors Anthony Glenning, Dr Leigh Farrell, Deena Shiff and Alice Williams.

Adding a director who has run a large software business through a cloud transition, and who now invests in technology companies, broadens that mix. Pro Medicus' flagship Visage 7 platform is sold on long-term, transaction-based contracts, and the company's future depends on continuing to win and implement large enterprise deals. Experience in scaling software businesses is directly relevant to that model.

The appointment also adds independent governance depth at a time when the company's size and profile have grown significantly. Mr Reed's time as a private equity investor in software businesses may also bring an outside perspective on valuation, capital allocation and competitive dynamics in enterprise technology, areas that matter for a company holding a substantial cash balance and no debt.

The business Reed is joining

Pro Medicus trong FY26 results on 18 August 2026. Revenue rose 22.9 per cent to $261.7 million, and underlying net profit after tax rose 24.1 per cent to $144.7 million. The company's EBIT Margin was 74.9 per cent, up from 74.0 per cent, and it declared a fully Franked Dividend of 69 cents per share, up 25.5 per cent. Statutory net profit was $265.3 million, up 130.3 per cent, with the underlying figure used by the company as the like-for-like measure of trading performance.